Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Marc Wilson Biography and Net Worth

CFO of Crinetics Pharmaceuticals

Marc Wilson has served as our Chief Financial Officer since January 2018. Prior to Crinetics, Mr. Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, Inc., from September 2014 to January 2018. From 2010 to 2014, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics, until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson worked at Neurocrine Biosciences, Inc. from 2007 to 2010. Mr. Wilson began his career with PricewaterhouseCoopers LLP and is a certified public accountant.

Mr. Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.

What is Marc Wilson's net worth?: The estimated net worth of Marc Wilson is at least $6.23 million as of September 26th, 2024. Mr. Wilson owns 111,092 shares of Crinetics Pharmaceuticals stock worth more than $6,227,818 as of November 22nd. This net worth evaluation does not reflect any other assets that Mr. Wilson may own. Additionally, Mr. Wilson receives an annual salary of $642,250.00 as CFO at Crinetics Pharmaceuticals. Learn More about Marc Wilson's net worth.
How old is Marc Wilson?: Mr. Wilson is currently 45 years old. There are 5 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who is 61 years old. Learn More on Marc Wilson's age.
What is Marc Wilson's salary?: As the CFO of Crinetics Pharmaceuticals, Inc., Mr. Wilson earns $642,250.00 per year. There are 4 executives that earn more than Mr. Wilson. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on Marc Wilson's salary.
How do I contact Marc Wilson?: The corporate mailing address for Mr. Wilson and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Marc Wilson's contact information.
Has Marc Wilson been buying or selling shares of Crinetics Pharmaceuticals?: Marc Wilson has not been actively trading shares of Crinetics Pharmaceuticals in the last ninety days. Most recently, Marc Wilson sold 25,000 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $51.11, for a transaction totalling $1,277,750.00. Following the completion of the sale, the chief financial officer now directly owns 111,092 shares of the company's stock, valued at $5,677,912.12. Learn More on Marc Wilson's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 34 times. They sold a total of 560,048 shares worth more than $26,278,027.53. The most recent insider tranaction occured on October, 3rd when insider Dana Pizzuti sold 14,375 shares worth more than $785,306.25. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 10/3/2024.

Marc Wilson Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/26/2024	Sell	25,000	$51.11	$1,277,750.00	111,092
7/25/2024	Sell	19,056	$53.88	$1,026,737.28	111,092
7/15/2024	Sell	25,000	$55.00	$1,375,000.00	111,092
6/28/2024	Sell	32,129	$43.61	$1,401,145.69	111,092
3/19/2024	Sell	6,942	$42.91	$297,881.22	110,630
1/2/2024	Sell	10,000	$35.47	$354,700.00	96,055
11/1/2023	Sell	10,000	$28.75	$287,500.00	95,601
6/20/2023	Sell	30,922	$19.97	$617,512.34	95,158

Marc Wilson Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $56.06

$55.34

$57.10

50 Day Range

MA: $55.32

$49.82

$60.69

2 Week Range

Now: $56.06

$30.50

$62.53

Volume

1,037,121 shs

Average Volume

783,880 shs

Market Capitalization

$5.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Marc Wilson Biography and Net Worth

What is Marc Wilson's net worth?

How old is Marc Wilson?

What is Marc Wilson's salary?

How do I contact Marc Wilson?

Has Marc Wilson been buying or selling shares of Crinetics Pharmaceuticals?

Who are Crinetics Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Crinetics Pharmaceuticals?